Development of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenza
Award Notice Posted
- Solicitation number
- 75A50125C00017
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Awarded
- to Cidara Therapeutics Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50125C00017 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- San Diego, California 92121, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded contract 75A50125C00017 to CIDARA THERAPEUTICS INC on September 30, 2025, with a total contract value of $339,189,481.00. The contract focuses on the development of CD388 as a long-lasting prophylactic anti-viral option specifically designed to provide protection against health impacts caused by influenza. This substantial award represents a significant investment by the federal government in advancing antiviral therapeutic capabilities for pandemic preparedness and public health protection. The contract supports the development of preventive medical countermeasures that could provide extended protection against influenza viruses, aligning with the agency's mission to enhance national health security and emergency preparedness.
Notice text
Awarded contract 75A50125C00017 to CIDARA THERAPEUTICS INC for 339189481.00 on 2025-09-30.
Notice history
5 of 13 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity